🔴 Tscan Therapeutics is trading 5.5% down in pre-market with no clear company-specific catalyst identified

Tscan Therapeutics is trading at $0.21, down -5.54% in pre-market, with no clear company-specific catalyst identified.

• The company’s press-release page lists October 6, 2026, as its latest release date.
• Biotech was up 3.64% pre-market, which does not explain the stock’s decline in the same direction.
• The decline follows a volatile week, but available information does not establish a specific cause; no volume or trading-activity data was provided.